Shire faces RoI test under vision-loving new CEO
This article was originally published in Scrip
Shire Pharmaceuticals is known for its acquisitive buy-late, maximize-market strategy. Flemming Ornskov, the company's new CEO, plans to continue that approach, firstly by applying it to acquisitions in ophthalmology, an area in which he has specialized. However, with many recent acquisitions yet to mature to revenue-generation, and with big indication areas for Shire like ADHD at risk from generic and branded competition, the pressure is on the new CEO – even before he officially starts work.
You may also be interested in...
The confluence of data science and molecular biology fuels expectations among biopharma industry leaders for another year of breakthrough innovation in human therapeutics. More than 70 executives and experts reveal what they are most excited about on the technology front.
Biopharma executives see value-based pricing as an increasingly important topic for the sector in 2023, while the US Inflation Reduction Act will have a major impact on portfolio strategies.
Headwinds of political instability, violent conflict, inflation and recession accompany us into 2023. Scrip surveyed industry leaders on the impacts for biopharma.